(RTTNews) - Baxter International Inc. (BAX) has agreed to buy Cheetah Medical, a provider of non-invasive hemodynamic monitoring technologies, in a deal consists of an upfront cash consideration of $190 million, with potential for an additional $40 million. Baxter anticipates the transaction to be immaterial to earnings in 2019 and 2020.
Headquartered in Boston and Tel Aviv, Israel, Cheetah Medical will provide Baxter with its non-invasive hemodynamic monitoring systems, including the latest Starling SV system. The CHEETAH Starling SV provides immediate assessments of fluid responsiveness, enabling clinicians to make more informed treatment for their patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.